Drugs / Leish-111f
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT00486382 | Apr 2007 → Nov 2008 | visceral leishmaniasis | Access to Advanced Health Institute (AAHI) | Completed | No outcome recorded |
| Phase 1 | NCT00121849 | Aug 2005 → Feb 2006 | cutaneous leishmaniasis | Access to Advanced Health Institute (AAHI) | Completed | No outcome recorded |
| Phase 1 | NCT00111553 | Oct 2004 → Aug 2006 | cutaneous leishmaniasis | Access to Advanced Health Institute (AAHI) | Completed | No outcome recorded |
| Phase 1 | NCT00111514 | Jul 2004 → May 2006 | mucocutaneous leishmaniasis | Access to Advanced Health Institute (AAHI) | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00121862 | Aug 2005 → Mar 2006 | cutaneous leishmaniasis | Access to Advanced Health Institute (AAHI) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Leish-111f | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00486382 ↗ |
| Known as | Leish-111f protein | “In addition, the safety and immunogenicity of the vaccine will be compared to that of the Leish-111f protein (10 μg) given alone.” NCT00121862 ↗ |
| Modality | Protein / enzyme biologic | “5, 10, or 20 μg recombinant Leishmania polyprotein LEISH-F1 antigen” PMID 20851080 ↗ Sep 2010 |
| Route | Subcutaneous | “The study injections were given subcutaneously on Days 0, 28, and 56” PMID 20851080 ↗ Sep 2010 |